机构：[1]Department of NuclearMedicine, The Affiliated Hospital of Southwest Medical University/Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province/and Institute of NuclearMedicine, SouthwestMedical University, Luzhou, Sichuan, China.
This study was supported in part by research foundation
projects from Luzhou Science and Technology Department (20107) and (2022-
JYJ-118) and The Affiliated Hospital of Southwest Medical University (20087).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|3 区医学
小类|3 区核医学
最新[2023]版：
大类|3 区医学
小类|3 区核医学
第一作者：
第一作者机构：[1]Department of NuclearMedicine, The Affiliated Hospital of Southwest Medical University/Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province/and Institute of NuclearMedicine, SouthwestMedical University, Luzhou, Sichuan, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of NuclearMedicine, The Affiliated Hospital of Southwest Medical University/Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province/and Institute of NuclearMedicine, SouthwestMedical University, Luzhou, Sichuan, China.[*1]Department of Nuclear Medicine, The Affiliated Hospital of SouthwestMedical University, No. 25 TaiPing St, Jiangyang District, Luzhou, Sichuan, 646000, China.
推荐引用方式(GB/T 7714)：
Yang Hongyu,Liu Huipan,Li Hongmei,et al.177 Lu-FAP-2286 Therapy in a Metastatic Bone Malignant Solitary Fibrous Tumor[J].Clinical Nuclear Medicine.2024,49(5):472-474.doi:10.1097/RLU.0000000000005168.
APA：
Yang Hongyu,Liu Huipan,Li Hongmei,Zhang Yu&Chen Yue.(2024).177 Lu-FAP-2286 Therapy in a Metastatic Bone Malignant Solitary Fibrous Tumor.Clinical Nuclear Medicine,49,(5)
MLA：
Yang Hongyu,et al."177 Lu-FAP-2286 Therapy in a Metastatic Bone Malignant Solitary Fibrous Tumor".Clinical Nuclear Medicine 49..5(2024):472-474
